NasdaqCM:SAVA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-112	N/A	N/A	1
12/31/2025	100	-41	N/A	N/A	2
12/31/2024	N/A	-60	N/A	N/A	2
6/30/2024	N/A	-15	-86	-86	N/A
3/31/2024	N/A	-48	-88	-88	N/A
12/31/2023	N/A	-97	-82	-82	N/A
9/30/2023	N/A	-95	-81	-81	N/A
6/30/2023	N/A	-90	-77	-76	N/A
3/31/2023	N/A	-83	-70	-67	N/A
12/31/2022	N/A	-76	-80	-78	N/A
9/30/2022	N/A	-71	-67	-64	N/A
6/30/2022	N/A	-61	-81	-57	N/A
3/31/2022	N/A	-46	-74	-51	N/A
12/31/2021	N/A	-32	-52	-30	N/A
9/30/2021	N/A	-21	-45	-23	N/A
6/30/2021	N/A	-13	-11	-11	N/A
3/31/2021	N/A	-9	-6	-6	N/A
12/31/2020	N/A	-6	-5	-5	N/A
9/30/2020	N/A	-5	-5	-5	N/A
6/30/2020	N/A	-4	-3	-3	N/A
3/31/2020	N/A	-4	-3	-3	N/A
12/31/2019	N/A	-5	-3	-3	N/A
9/30/2019	N/A	-4	-3	-2	N/A
6/30/2019	N/A	-4	-3	-3	N/A
3/31/2019	N/A	-6	-4	-4	N/A
12/31/2018	N/A	-7	-5	-5	N/A
9/30/2018	N/A	-8	-6	-6	N/A
6/30/2018	N/A	-10	-6	-6	N/A
3/31/2018	N/A	-11	N/A	-8	N/A
12/31/2017	N/A	-12	N/A	-8	N/A
9/30/2017	N/A	-12	N/A	-10	N/A
6/30/2017	N/A	-13	N/A	-10	N/A
3/31/2017	N/A	-12	N/A	-11	N/A
12/31/2016	N/A	-15	N/A	-12	N/A
9/30/2016	N/A	-17	N/A	-13	N/A
6/30/2016	N/A	-17	N/A	-12	N/A
3/31/2016	N/A	-17	N/A	-11	N/A
12/31/2015	N/A	-14	N/A	-9	N/A
9/30/2015	N/A	-12	N/A	-8	N/A
6/30/2015	N/A	-12	N/A	-7	N/A
3/31/2015	N/A	-12	N/A	-8	N/A
12/31/2014	N/A	-12	N/A	-10	N/A
9/30/2014	35	23	N/A	-8	N/A
6/30/2014	37	26	N/A	-9	N/A
3/31/2014	39	29	N/A	-8	N/A
12/31/2013	41	32	N/A	-7	N/A
9/30/2013	8	-3	N/A	-7	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SAVA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SAVA今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: SAVA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SAVAの収益 ( 24.4% ) US市場 ( 8.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: SAVAの収益 ( 24.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SAVAの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Cassava Sciences 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus EPS estimates upgraded to US$0.77 loss

Forecast to breakeven in 2023

Price target increased to US$84.00

Price target decreased to US$58.67

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Recent updates

Cassava Sciences, Inc. Appoints Richard Barry as Chief Executive Officer

New minor risk - Profitability

New major risk - Revenue and earnings growth

Cassava Sciences, Inc. Announces Demise of Sanford Robertson, Board Member

Cassava Sciences, Inc. Announces Expansion of Open-Label Extension Trials

Cassava Sciences: Turning The Corner Into A Brick Wall

Cassava Sciences, Inc. Announces Chief Executive Officer Changes

New minor risk - Profitability

New major risk - Revenue and earnings growth

New minor risk - Profitability

Independent Director exercised options to buy US$3.9m worth of stock.

Cassava Sciences, Inc., Annual General Meeting, May 09, 2024

Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer’s Disease Dementia

Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Growth-Dynamic Index

Cassava Sciences, Inc. Announces Board Appointments

New major risk - Revenue and earnings growth

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’S Disease

Cassava Sciences, Inc. Announces Positive Safety Findings Based on Interim Magnetic Resonance Imaging Brain Data from Alzheimer's Patients

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

New minor risk - Share price stability

Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. Announces Positive Interim Safety Review of Simufilam On-Going Phase 3 Trials in Patients with Alzheimer’s Disease

Independent Director recently bought US$308k worth of stock

New major risk - Revenue and earnings growth

Cassava Sciences, Inc Announces Top-Line Clinical Results from Its Cognition Maintenance Study

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Cassava Sciences, Inc. Announces the Publication of A New Paper in Frontiers in Aging

Founder exercised options and sold US$480k worth of stock

Lead Independent Director exercised options to buy US$259k worth of stock.

Independent Director recently bought US$2.3m worth of stock

Consensus EPS estimates upgraded to US$0.77 loss

We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate

Forecast to breakeven in 2023

Cassava Sciences, Inc. Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

Cassava Sciences, Inc. Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

Price target increased to US$84.00

Cassava Sciences, Inc. Announces Executive Changes

Cassava Sciences, Inc. Announces Completion of Dosing in Open-Label Study of Simufilam for Alzheimer’s Disease

Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans

Cassava Sciences, Inc. Appoints Christopher Cook as Senior Vice President and General Counsel

Cassava Sciences Announces Initiation of an Open-Label Extension Study

Cassava Sciences begins extension study of Alzheimer's drug simufilam

Cassava Sciences Stock: Huge Returns Or Catastrophic Losses

Cassava Sciences: Trying To Manage Expectations

Lead Independent Director exercised options to buy US$86k worth of stock.

Cassava Sciences reaches over five-month high on rising volumes

Cassava Sciences Looks As Good Of A Purchase As Ever

Cassava Sciences stock jumps 10% after director buys $860K shares

Chief Clinical Development Officer recently bought US$61k worth of stock

Lead Independent Director recently bought US$2.1m worth of stock

Cassava Sciences rally continues as stock up 39%

Price target decreased to US$58.67

Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results

Cassava Sciences GAAP EPS of -$0.48 misses by $0.06

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug

Cassava Sciences And Alzheimer's Disease: A Precipitious Path

Founder exercised options and sold US$249k worth of stock

Chief Medical Officer & Director exercised options and sold US$81k worth of stock

Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate

Founder exercised options to buy US$1.0m worth of stock.

Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait

3 Key Points To Remember About Cassava Sciences

Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences

Lead Independent Director exercised options to buy US$180k worth of stock.

Forecast to breakeven in 2022